Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group

Francesco Sclafani*, Elisa Fontana, Lucjan Wyrwicz, Anna Dorothea Wagner, Juan W. Valle, Elizabeth Smyth, Mark Peeters, Radka Obermannova, Cindy Neuzillet, Manfred P. Lutz, Thibaud Koessler, Irit Ben-Aharon, Dirk Arnold, Maria Alsina, Markus Moehler

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients’ needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.

Original languageEnglish
Pages (from-to)188-197
Number of pages10
JournalClinical Colorectal Cancer
Volume21
Issue number3
DOIs
StatePublished - Sep 2022
Externally publishedYes

Keywords

  • Clinical trials
  • Colorectal cancers
  • Esophago-gastric cancers
  • Hepato-pancreatico-biliary cancers
  • Meeting

Fingerprint

Dive into the research topics of 'Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group'. Together they form a unique fingerprint.

Cite this